Supplemental Materials

Yoshida *et al*.

Molecular sensitization to trastuzumab via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells



Supplemental Fig. 1

Western blot analysis for HER2-wt (185kDa) and p95HER2 (95kDa).
Human breast cancer SKBR3 and BT474 cells were initially incubated with 50 mg/ml trastuzumab (Tzb) for 1 month followed by 100 mg/ml trastuzumab for 2 months. *Cells were cultured in the absence of trastuzumab for 5 days before analysis. Equivalent amounts of protein from whole cell lysates were loaded into each lane. Blots were probed with anti-HER2-ECD antibody and visualized by using an ECL detection system. Equal loading of samples was confirmed by stripping each blot and reprobing with anti-β-actin.

Supplemental Materials

Yoshida *et al*.

Molecular sensitization to trastuzumab via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells



Supplemental Fig. 2

Trastuzumab-mediated ADCC activity on human gastric cancer cells with various levels of HER2 expression.
The cytotoxic reactivity of PBMCs against HER2-positive MKN7 or low HER2-expressing MKN1 or MKN28 human gastric cancer cells was assessed in the presence of 10 mg/ml of trastuzumab or control rituximab by a 4-h ^{51}Cr-release assay.